NICE Draft Guidance Reverses Endorsement of Oncotype Dx to Guide Chemotherapy

Jan 10, 2018

|

NEW YORK (GenomeWeb) – A draft document published today by the UK's National Institute for Health and Care Excellence (NICE) reverses a previous endorsement for the use of Genomic Health's Oncotype Dx test in guiding chemotherapy decisions for breast cancer patients.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

NICE Draft Guidance Reverses Endorsement of Oncotype Dx to Guide Chemotherapy

To read the full story....

Breaking News

Palmetto Expands Coverage for Decipher Biosciences Prostate Cancer Test

Cepheid Multiplex SARS-CoV-2, Flu, RSV Test Nabs FDA Emergency Use Authorization

ASU Team Wins $6M in Government Funding to Develop Rapid Saliva Testing System for Coronavirus

Biovica Files FDA 510(k) Submission for Breast Cancer Treatment Response Assay

Genetron, CStone Launch Clinical Trial to Develop CDx for Cancer Drug Avapritinib

Natera Cancer Liquid Biopsy Test Coverage to Expand Under New Draft LCD

Featured White Papers

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

What's Popular?

Cepheid Multiplex SARS-CoV-2, Flu, RSV Test Nabs FDA Emergency Use Authorization

United Airlines Launches COVID-19 Testing Program for Travelers to Hawaii

ASU Team Wins $6M in Government Funding to Develop Rapid Saliva Testing System for Coronavirus

Abacus Diagnostica Readying Multiplex RT-PCR Test for SARS-CoV-2, Flu, RSV

FDA Revises Emergency Use Authorization for Abbott Point-of-Care SARS-CoV-2 Test

Sponsorships